Medicare and Medicaid have spent an estimated $23.8 billion on 18 FDA accelerated approval (AA) drugs with incomplete confirmatory trials that missed their planned completion dates, the HHS Office of Inspector General (OIG) said in a new report released Friday, adding that the drugs have been “staying on the market — and being administered to patients — for years without the predicted clinical benefit being verified.”
Source: Drug Industry Daily